Cardiovascular risk in women with nonclassical congenital adrenal hyperplasia
© The Author(s) 2024. Published by Oxford University Press on behalf of the Endocrine Society..
CONTEXT: The outcomes related to cardiovascular risk (CVR) in patients with nonclassical form of congenital adrenal hyperplasia (NCAH) are unknown, especially those related to therapeutic options, including low doses of glucocorticoids (GCs) or oral contraceptive pills.
OBJECTIVES: to analyze CVR by markers of atherosclerosis in females with nonclassical form according to therapeutic options.
DESIGN AND SETTING: a cross-sectional study at a tertiary center.
PATIENTS AND METHODS: Forty-seven females with NCAH (33.4 ± 10 years) were subdivided into: G1 (n = 28) treated with dexamethasone (0.14 ± 0.05 mg/m2/day); G2 (n = 19) with oral contraceptive pills; and G3 (30 matched controls). CVR was analyzed through serum lipids, HOMA-IR, inflammatory cytokines levels and quantitative image evaluations (pulse wave velocity-PWV, endothelial function by flow mediated dilatation-FMD, carotid intima media thickness-CIMT and visceral fat-VAT by abdominal tomography.
RESULTS: There were no statistically significant differences in BMI, HOMA-IR, HDL-cholesterol, or triglyceride levels among groups (p > 0.05). Serum interleukin-6 levels were higher in G1 than in G2 (p = 0.048), and interleukin-8 levels were higher in G1 than in G2/3 (p = 0.008). There were no statistically significant differences in VAT, PWV, FMD or CIMT among groups (p > 0.05). In multivariable regression analysis, there was no statistically significant association between glucocorticoid dose and evaluated outcomes.
CONCLUSION: Adult females with NCAH did not show increased CVR using methodologies for detection of precocious atherosclerosis. Although patients receiving dexamethasone therapy had increased IL-6 and 8 levels, these data were not associated with radiological markers of atherosclerosis. Our cohort was composed of young adults and should be reevaluated in a long-term follow-up.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
The Journal of clinical endocrinology and metabolism - (2024) vom: 11. März |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Costa, Fernanda Cavalieri [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Cardiovascular risk |
|---|
| Anmerkungen: |
Date Revised 11.03.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1210/clinem/dgae155 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369566165 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369566165 | ||
| 003 | DE-627 | ||
| 005 | 20240312234558.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240312s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1210/clinem/dgae155 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1324.xml |
| 035 | |a (DE-627)NLM369566165 | ||
| 035 | |a (NLM)38466890 | ||
| 035 | |a (PII)dgae155 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Costa, Fernanda Cavalieri |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Cardiovascular risk in women with nonclassical congenital adrenal hyperplasia |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 11.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a © The Author(s) 2024. Published by Oxford University Press on behalf of the Endocrine Society. | ||
| 520 | |a CONTEXT: The outcomes related to cardiovascular risk (CVR) in patients with nonclassical form of congenital adrenal hyperplasia (NCAH) are unknown, especially those related to therapeutic options, including low doses of glucocorticoids (GCs) or oral contraceptive pills | ||
| 520 | |a OBJECTIVES: to analyze CVR by markers of atherosclerosis in females with nonclassical form according to therapeutic options | ||
| 520 | |a DESIGN AND SETTING: a cross-sectional study at a tertiary center | ||
| 520 | |a PATIENTS AND METHODS: Forty-seven females with NCAH (33.4 ± 10 years) were subdivided into: G1 (n = 28) treated with dexamethasone (0.14 ± 0.05 mg/m2/day); G2 (n = 19) with oral contraceptive pills; and G3 (30 matched controls). CVR was analyzed through serum lipids, HOMA-IR, inflammatory cytokines levels and quantitative image evaluations (pulse wave velocity-PWV, endothelial function by flow mediated dilatation-FMD, carotid intima media thickness-CIMT and visceral fat-VAT by abdominal tomography | ||
| 520 | |a RESULTS: There were no statistically significant differences in BMI, HOMA-IR, HDL-cholesterol, or triglyceride levels among groups (p > 0.05). Serum interleukin-6 levels were higher in G1 than in G2 (p = 0.048), and interleukin-8 levels were higher in G1 than in G2/3 (p = 0.008). There were no statistically significant differences in VAT, PWV, FMD or CIMT among groups (p > 0.05). In multivariable regression analysis, there was no statistically significant association between glucocorticoid dose and evaluated outcomes | ||
| 520 | |a CONCLUSION: Adult females with NCAH did not show increased CVR using methodologies for detection of precocious atherosclerosis. Although patients receiving dexamethasone therapy had increased IL-6 and 8 levels, these data were not associated with radiological markers of atherosclerosis. Our cohort was composed of young adults and should be reevaluated in a long-term follow-up | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a cardiovascular risk | |
| 650 | 4 | |a carotid intima media thickness | |
| 650 | 4 | |a endothelial function | |
| 650 | 4 | |a nonclassical congenital adrenal hyperplasia | |
| 650 | 4 | |a pulse wave velocity | |
| 650 | 4 | |a visceral fat | |
| 700 | 1 | |a Gomes, Larissa Garcia |e verfasserin |4 aut | |
| 700 | 1 | |a de Lima, Thais Martins |e verfasserin |4 aut | |
| 700 | 1 | |a Bortolotto, Luiz Aparecido |e verfasserin |4 aut | |
| 700 | 1 | |a Hong, Valeria |e verfasserin |4 aut | |
| 700 | 1 | |a Verardino, Renata |e verfasserin |4 aut | |
| 700 | 1 | |a de Souza Rocha, Manoel |e verfasserin |4 aut | |
| 700 | 1 | |a Ueda, Serli Kiyomi Nakao |e verfasserin |4 aut | |
| 700 | 1 | |a de Miranda, Mirela Costa |e verfasserin |4 aut | |
| 700 | 1 | |a de Souza, Heraldo Possolo |e verfasserin |4 aut | |
| 700 | 1 | |a Latronico, Ana Claudia |e verfasserin |4 aut | |
| 700 | 1 | |a Mendonca, Berenice Bilharinho |e verfasserin |4 aut | |
| 700 | 1 | |a Bachega, Tania A S S |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Journal of clinical endocrinology and metabolism |d 1945 |g (2024) vom: 11. März |w (DE-627)NLM00001821X |x 1945-7197 |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:11 |g month:03 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1210/clinem/dgae155 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 11 |c 03 | ||